Skip to content

Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases

Phase I Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00465023
Enrollment
16
Registered
2007-04-24
Start date
2003-06-30
Completion date
2017-01-31
Last updated
2017-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma, Hepatic Metastases, Hepatocellular Cancer

Keywords

proton beam irradiation, liver cancer

Brief summary

The main purpose of this study is to determine if high doses of radiation using proton beam can be given safely with low and acceptable side effects. We will also gather information to determine the ability of proton beam to destroy cancer cells in the liver. There are two types of external radiation treatments (proton beam and photon beam). Proton beam radiation is a very accurate kind of treatment that has been shown to affect less normal tissue than a regular radiation beam. The accuracy allows us to more safely increase the amount of radiation delivered to eliminate cancer and may potentially reduce the side effects normally experienced with standard radiation therapy.

Detailed description

* Participants will receive treatment as an outpatient at the Northeast Proton Treatment Center located at the Massachusetts General Hospital. * Since we are looking for the highest dose of proton beam radiation that can be given to people safely, not everyone who participates in this study will be receiving the same amount of radiation. Small groups of people will be enrolled and given a certain dose of radiation. If they tolerate it well, the next small group of people enrolled will receive a higher dose. This will continue until we find the highest dose that can be given without causing serious or unmanageable side effects. * Radiation treatment to the liver will be given once a day, 5 days a week (Monday-Friday), for 3 weeks. Each treatment takes about 10-20 minutes. * A physical examination, medical history, and blood tests will be taken once a week for 3 weeks during radiation therapy. Follow-up visits will occur every 3 months for 2 years, and every 6 months thereafter for 3 years, and then annually thereafter.

Interventions

Once a day, 5 days a week (Monday-Friday) for 3 weeks.

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Dana-Farber Cancer Institute
CollaboratorOTHER
Brigham and Women's Hospital
CollaboratorOTHER
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Biopsy proven unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases. * Primary lesion size of 6cm or less in greatest diameter * Single or multinodular tumors (up to 3) * 18 years of age or older * No evidence of extrahepatic tumor * Karnofsky performance status of 70-100 * If patient has underlying cirrhosis, only Child's classification Group A or Group B * Adequate renal function * Expected survival of greater than three months

Exclusion criteria

* Pregnant or lactating women * Evidence of non-hepatic metastatic disease * Local conditions or systemic illnesses which would reduce the local tolerance to radiation treatment, such as serious local injuries, active collagen vascular disease, etc. * Prior radiation treatment to affected region * Serious psychiatric illness which would limit compliance with treatment

Design outcomes

Primary

MeasureTime frame
To determine the maximum tolerated dose (MTD) of proton beam irradiation in patients with unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.4 years

Secondary

MeasureTime frame
To determine safety and tolerance of this treatment program4 years
to evaluate tumor response, local control and survival in this patient population.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026